RBS: With the approval of Ellavie in Sweden last week, ACR has demonstrated its ability to deliver on milestones. It is this consistent performance that sees us rate it as a stand-out stock in the life science sector.
RBS have increased their price target to A$4.06 (from A$3.88). Buy retained.
RBS: With the approval of Ellavie in Sweden last week, ACR has...
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.69M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 434 | 5.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.8¢ | 17258 | 1 |
View Market Depth
| Last trade - 16.12pm 04/10/2024 (20 minute delay) ? |
| ACR (ASX) Chart |
Day chart unavailable